Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy
1
Department of Biomedical Sciences, Chonnam National University Medical School, 264, Seoyang-ro, Jeollanam-do 58128, Korea
2
Department of Polymer Science and Engineering, Chungnam National University, 99 Daehak-ro, Yuseoung-gu, Daejeon 34134, Korea
*
Authors to whom correspondence should be addressed.
Academic Editor: Rita Cortesi
Molecules 2020, 25(19), 4377; https://doi.org/10.3390/molecules25194377
Received: 3 September 2020
/
Revised: 22 September 2020
/
Accepted: 22 September 2020
/
Published: 23 September 2020
(This article belongs to the Special Issue Preparation, Characterization, and Effect of Lipid Nanoparticles Used in Different Application Fields)
Cancer represents one of the most dangerous diseases, with 1.8 million deaths worldwide. Despite remarkable advances in conventional therapies, these treatments are not effective to completely eradicate cancer. Nanotechnology offers potential cancer treatment based on formulations of several nanoparticles (NPs). Liposomes and polymeric nanoparticle are the most investigated and effective drug delivery systems (DDS) for cancer treatment. Liposomes represent potential DDS due to their distinct properties, including high-drug entrapment efficacy, biocompatibility, low cost, and scalability. However, their use is restricted by susceptibility to lipid peroxidation, instability, burst release of drugs, and the limited surface modification. Similarly, polymeric nanoparticles show several chemical modifications with polymers, good stability, and controlled release, but their drawbacks for biological applications include limited drug loading, polymer toxicity, and difficulties in scaling up. Therefore, polymeric nanoparticles and liposomes are combined to form polymer-lipid hybrid nanoparticles (PLHNPs), with the positive attributes of both components such as high biocompatibility and stability, improved drug payload, controlled drug release, longer circulation time, and superior in vivo efficacy. In this review, we have focused on the prominent strategies used to develop tumor targeting PLHNPs and discuss their advantages and unique properties contributing to an ideal DDS.
View Full-Text
Keywords:
cancer; nanotechnology; polymeric nanoparticles; liposomes; polymer-lipid hybrid nanoparticles (PLHNPs); targeting ligands; anticancer therapy
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Mohanty, A.; Uthaman, S.; Park, I.-K. Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy. Molecules 2020, 25, 4377. https://doi.org/10.3390/molecules25194377
AMA Style
Mohanty A, Uthaman S, Park I-K. Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy. Molecules. 2020; 25(19):4377. https://doi.org/10.3390/molecules25194377
Chicago/Turabian StyleMohanty, Ayeskanta, Saji Uthaman, and In-Kyu Park. 2020. "Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy" Molecules 25, no. 19: 4377. https://doi.org/10.3390/molecules25194377
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
